TrialBritish journal of cancer2023

Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.

Nicola Gaynor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.